Literature DB >> 19415424

Key points in migraine prophylaxis: patient perspective.

Domenico D'Amico1, S J Tepper.   

Abstract

Migraine is a chronic neurological condition with heterogeneous presentation. It is associated with significant pain, disability, and diminished quality of life in a large proportion of patients. Patients with severe and/or frequent migraines require prophylaxis, which implies daily administration of anti-migraine compounds for several months, with potential adverse events or contraindications. This paper reviews the main factors influencing patient acceptance of anti-migraine prophylaxis, providing practical suggestions to maximize patient agreement with, and adherence to, preventive treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19415424     DOI: 10.1007/s10072-009-0056-4

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  30 in total

1.  Divalproex sodium in migraine prophylaxis: a dose-controlled study.

Authors:  J Klapper
Journal:  Cephalalgia       Date:  1997-04       Impact factor: 6.292

2.  An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score.

Authors:  W F Stewart; R B Lipton; J Whyte; A Dowson; K Kolodner; J N Liberman; J Sawyer
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

3.  Efficacy of gabapentin in migraine prophylaxis.

Authors:  N T Mathew; A Rapoport; J Saper; L Magnus; J Klapper; N Ramadan; B Stacey; S Tepper
Journal:  Headache       Date:  2001-02       Impact factor: 5.887

4.  Determinants of patient satisfaction with migraine therapy.

Authors:  G M Davies; N Santanello; R Lipton
Journal:  Cephalalgia       Date:  2000-07       Impact factor: 6.292

5.  Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan.

Authors:  Fernando Iglesias Díez; Andreas Straube; Giorgio Zanchin
Journal:  J Neurol       Date:  2007-03-02       Impact factor: 4.849

6.  Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial.

Authors:  Hans-Christoph Diener; Reto Agosti; Gianni Allais; Paul Bergmans; Gennaro Bussone; Brendan Davies; Mustafa Ertas; Michel Lanteri-Minet; Uwe Reuter; Margarita Sánchez Del Río; Jean Schoenen; Susanne Schwalen; Joop van Oene
Journal:  Lancet Neurol       Date:  2007-11-07       Impact factor: 44.182

7.  Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire.

Authors:  A J Dowson; S J Tepper; V Baos; F Baudet; D D'Amico; S Kilminster
Journal:  Curr Med Res Opin       Date:  2004-07       Impact factor: 2.580

8.  Patterns of use of triptans and reasons for switching them in a tertiary care migraine population.

Authors:  Fred D Sheftell; Michele Feleppa; Stewart J Tepper; Michel Volcy; Alan M Rapoport; Marcelo E Bigal
Journal:  Headache       Date:  2004 Jul-Aug       Impact factor: 5.887

Review 9.  Migraine prevalence. A review of population-based studies.

Authors:  W F Stewart; A Shechter; B K Rasmussen
Journal:  Neurology       Date:  1994-06       Impact factor: 9.910

10.  The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials.

Authors:  Carl Dahlöf; Elizabeth Loder; Merle Diamond; Marcia Rupnow; George Papadopoulos; Lian Mao
Journal:  Health Qual Life Outcomes       Date:  2007-10-04       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.